Promoter holding
64.27%
AP
Arch Pharmalabs Limited - Due diligence report
A 360° intelligence report on Arch Pharmalabs: trust score, financial health, credit view, compliance, directors, growth and distress signal…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Arch Pharmalabs — 360° Intelligence Report
Generated from MCA filings & public records60/100
Trust Score
Moderate
Arch Pharmalabs is assessed as Moderate with a Trust Score of 60/100. Arch Pharmalabs is a public limited indian non-government company incorporated in 1993, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Arch Pharmalabs Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
60/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
5/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (D).
Charges position: 51 open (5,668.24 cr) · 14 satisfied (311.84 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 44 | 48.0 cr |
| Axis Trustee Services Limited | 2 | 48.0 cr |
| Punjab National Bank | 2 | 48.0 cr |
| State Bank Of Indore | 2 | 48.0 cr |
| Canara Bank | 2 | 48.0 cr |
| Idbi Trusteeship Services Limited | 1 | 48.0 cr |
Compliance Score: 5/100 Caution Indicated
- Company status is "Under Cirp" - not Active.
- Last balance sheet is for Mar 2023 - filings overdue.
- Flagged by authority: EPFO, SEBI, DRT.
- Litigation present in 3 court forum(s).
- 5 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| VIKAS BIJAY KEDIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJENDRA PADMANABHAN KAIMAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNIL MANSUKHLAL PITRODA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANSHUL GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJIT ANNU KAMATH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJENDRA PADMANABHAN KAIMAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIKAS BIJAY KEDIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHISH MOHAN UJAGARE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajendrakumar Padmanabhan Kaimal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
4
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Vitalife Pharma Limited | Subsidiary Company | 74.00% |
| Arch Finechemicals Limited | Subsidiary Company | 74.00% |
| Arch Life Sciences Limited | Subsidiary Company | 74.00% |
| Arch Pharmalabs Fz Llc | Subsidiary Company | 74.00% |
| Kobo Biotech Limited | Associate Company | 74.00% |
Key managerial personnel: RAJENDRA PADMANABHAN KAIMAL (CFO) · AJIT ANNU KAMATH (Managing Director) · RAJENDRA PADMANABHAN KAIMAL (Whole-time director) · ASHISH MOHAN UJAGARE (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 55
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 33+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Under Cirp.
Compliance score is weak (5/100).
51 open charge(s) registered - assets are encumbered.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence36/100
Caution indicated
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment49/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 51 open charge(s) of 5,668.24 cr already registered.
- Compliance gaps should be priced into terms.
Investor view79/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Apr 2025
Director appointed
ANSHUL GUPTA (IRP/RP/Liquidator)
Director ceased
SANJAY GARG
29 Dec 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
30 Mar 2022
Securities allotted
320 Debentures - 32.00 cr raised
29 Mar 2022
Charge created
Others - 32.00 cr
20 Jul 2021
Charge created
Others - 5.00 Lakh
27 May 2021
Charge created
Others - 200.00 cr
30 May 2019
Director appointed
RAJENDRA PADMANABHAN KAIMAL (CFO)
29 Dec 2018
Director ceased
SUNIL MANSUKHLAL PITRODA
Director ceased
ASHISH MOHAN UJAGARE
01 Nov 2018
Director appointed
Rajendrakumar Padmanabhan Kaimal (Cfo)
31 Oct 2018
Director ceased
AJIT ANNU KAMATH
Director ceased
RAJENDRA PADMANABHAN KAIMAL
14 Jun 2018
Director appointed
ASHISH MOHAN UJAGARE (Whole-time director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
5 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of D from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Msn Life Sciences Private Limited | U24239TG2005PTC047655 | Hyderabad, Telangana, India |
| Nsl Sugars | U15429KA1999PLC026121 | Bangalore, Karnataka, India |
| Virchow Petrochemical Private Limited | U23209TG2003PTC041101 | Patancheru, Telangana, India |
| Visen | U24100MH1985PLC037350 | Mumbai, Maharashtra, India |
| Indian Cane Power Limited | U01542KA2002PLC030187 | Davangere, Karnataka, India |
| Lubrizol | U23201MH1966PTC013538 | Navi Mumbai, Maharashtra, India |
| The Andhra Sugars | L15420AP1947PLC000326 | Tanuku (Mdl), Andhra Pradesh, India |
| Jay Chemical Industries | U24119GJ2000PTC037683 | Ahmedabad, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Arch Pharmalabs before audits and certifications: compliance score 5/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Arch Pharmalabs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Arch Pharmalabs - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Caution indicated. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Arch Pharmalabs pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Arch Pharmalabs - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Arch Pharmalabs an active company?
Arch Pharmalabs has MCA status “Under Cirp” with a compliance score of 5/100 (Caution Indicated).
Is Arch Pharmalabs financially healthy?
Arch Pharmalabs has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Arch Pharmalabs?
Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Arch Pharmalabs?
Promoters hold a majority stake - exact percentages are in the full report. 9 active director(s) are on record.
Does Arch Pharmalabs have loans or charges against its assets?
51 open charge(s) are registered against its assets, and 14 earlier charge(s) stand satisfied.
Is Arch Pharmalabs up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 5/100 (Caution Indicated).
Is it risky to lend to Arch Pharmalabs?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
